{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:00:17Z","timestamp":1789012817270,"version":"build-2803163510"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,2,19]],"date-time":"2022-02-19T00:00:00Z","timestamp":1645228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,19]],"date-time":"2022-02-19T00:00:00Z","timestamp":1645228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s12185-022-03299-8","type":"journal-article","created":{"date-parts":[[2022,2,19]],"date-time":"2022-02-19T10:05:22Z","timestamp":1645265122000},"page":"645-658","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Novel treatments for myelofibrosis: beyond JAK inhibitors"],"prefix":"10.1007","volume":"115","author":[{"given":"Douglas","family":"Tremblay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5880-7972","authenticated-orcid":false,"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,19]]},"reference":[{"issue":"2","key":"3299_CR1","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.hoc.2020.12.001","volume":"35","author":"D Tremblay","year":"2021","unstructured":"Tremblay D, Yacoub A, Hoffman R. Overview of myeloproliferative neoplasms: history, pathogenesis, diagnostic criteria, and complications. Hematol Oncol Clin North Am. 2021;35(2):159\u201376. https:\/\/doi.org\/10.1016\/j.hoc.2020.12.001.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"13","key":"3299_CR2","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895\u2013901. https:\/\/doi.org\/10.1182\/blood-2008-07-170449.","journal-title":"Blood"},{"issue":"11","key":"3299_CR3","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/j.bbmt.2015.09.005","volume":"21","author":"HJ Deeg","year":"2015","unstructured":"Deeg HJ, Bredeson C, Farnia S, Ballen K, Gupta V, Mesa RA, et al. Hematopoietic cell transplantation as curative therapy for patients with myelofibrosis: long-term success in all age groups. Biol Blood Marrow Transplant. 2015;21(11):1883\u20137. https:\/\/doi.org\/10.1016\/j.bbmt.2015.09.005.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"25","key":"3299_CR4","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379\u201390. https:\/\/doi.org\/10.1056\/NEJMoa1311347.","journal-title":"N Engl J Med"},{"issue":"7","key":"3299_CR5","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/leu.2014.3","volume":"28","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014;28(7):1472\u20137. https:\/\/doi.org\/10.1038\/leu.2014.3.","journal-title":"Leukemia"},{"issue":"22","key":"3299_CR6","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","volume":"123","author":"R Rampal","year":"2014","unstructured":"Rampal R, Al-Shahrour F, Abdel-Wahab O, Patel JP, Brunel JP, Mermel CH, et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood. 2014;123(22):e123\u201333. https:\/\/doi.org\/10.1182\/blood-2014-02-554634.","journal-title":"Blood"},{"key":"3299_CR7","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2007.1.346","author":"R Hoffman","year":"2007","unstructured":"Hoffman R, Rondelli D. Biology and treatment of primary myelofibrosis. Hematology. 2007. https:\/\/doi.org\/10.1182\/asheducation-2007.1.346.","journal-title":"Hematology"},{"issue":"8","key":"3299_CR8","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.1182\/blood-2008-06-158386","volume":"112","author":"JJ Lataillade","year":"2008","unstructured":"Lataillade JJ, Pierre-Louis O, Hasselbalch HC, Uzan G, Jasmin C, Martyre MC, et al. Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence Blood. 2008;112(8):3026\u201335. https:\/\/doi.org\/10.1182\/blood-2008-06-158386.","journal-title":"From concept to evidence Blood"},{"issue":"8","key":"3299_CR9","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1038\/s41375-019-0379-y","volume":"33","author":"DAC Fisher","year":"2019","unstructured":"Fisher DAC, Miner CA, Engle EK, Hu H, Collins TB, Zhou A, et al. Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFkappaB signaling. Leukemia. 2019;33(8):1978\u201395. https:\/\/doi.org\/10.1038\/s41375-019-0379-y.","journal-title":"Leukemia"},{"issue":"5","key":"3299_CR10","first-page":"e45","volume":"32","author":"K Sokol","year":"2018","unstructured":"Sokol K, Tremblay D, Bhalla S, Rampal R, Mascarenhas JO. Implications of mutation profiling in myeloid malignancies-PART 2: myeloproliferative neoplasms and other myeloid malignancies. Oncology (Williston Park). 2018;32(5):e45\u201351.","journal-title":"Oncology (Williston Park)"},{"key":"3299_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04682-x","author":"S Verstovsek","year":"2021","unstructured":"Verstovsek S, Parasuraman S, Yu J, Shah A, Kumar S, Xi A, et al. Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval. Ann Hematol. 2021. https:\/\/doi.org\/10.1007\/s00277-021-04682-x.","journal-title":"Ann Hematol"},{"issue":"9","key":"3299_CR12","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa1110557.","journal-title":"N Engl J Med"},{"issue":"9","key":"3299_CR13","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787\u201398. https:\/\/doi.org\/10.1056\/NEJMoa1110556.","journal-title":"N Engl J Med"},{"issue":"5","key":"3299_CR14","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","volume":"1","author":"A Pardanani","year":"2015","unstructured":"Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol. 2015;1(5):643\u201351. https:\/\/doi.org\/10.1001\/jamaoncol.2015.1590.","journal-title":"JAMA Oncol"},{"issue":"9","key":"3299_CR15","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrc2210","volume":"7","author":"RL Levine","year":"2007","unstructured":"Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer. 2007;7(9):673\u201383. https:\/\/doi.org\/10.1038\/nrc2210.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3299_CR16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41467-019-13892-x","volume":"11","author":"E Mylonas","year":"2020","unstructured":"Mylonas E, Yoshida K, Frick M, Hoyer K, Christen F, Kaeda J, et al. Single-cell analysis based dissection of clonality in myelofibrosis. Nat Commun. 2020;11(1):73. https:\/\/doi.org\/10.1038\/s41467-019-13892-x.","journal-title":"Nat Commun"},{"issue":"3","key":"3299_CR17","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1182\/blood-2004-07-2864","volume":"105","author":"RA Mesa","year":"2005","unstructured":"Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005;105(3):973\u20137. https:\/\/doi.org\/10.1182\/blood-2004-07-2864.","journal-title":"Blood"},{"issue":"8","key":"3299_CR18","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/leu.2016.148","volume":"30","author":"CN Harrison","year":"2016","unstructured":"Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30(8):1701\u20137. https:\/\/doi.org\/10.1038\/leu.2016.148.","journal-title":"Leukemia"},{"issue":"4","key":"3299_CR19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3324\/haematol.2014.115840","volume":"100","author":"S Verstovsek","year":"2015","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica. 2015;100(4):479\u201388. https:\/\/doi.org\/10.3324\/haematol.2014.115840.","journal-title":"Haematologica"},{"issue":"9","key":"3299_CR20","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","volume":"130","author":"KJ Newberry","year":"2017","unstructured":"Newberry KJ, Patel K, Masarova L, Luthra R, Manshouri T, Jabbour E, et al. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood. 2017;130(9):1125\u201331. https:\/\/doi.org\/10.1182\/blood-2017-05-783225.","journal-title":"Blood"},{"issue":"3","key":"3299_CR21","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00277-017-3194-4","volume":"97","author":"AT Kuykendall","year":"2018","unstructured":"Kuykendall AT, Shah S, Talati C, Al Ali N, Sweet K, Padron E, et al. Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. Ann Hematol. 2018;97(3):435\u201341. https:\/\/doi.org\/10.1007\/s00277-017-3194-4.","journal-title":"Ann Hematol"},{"issue":"S1","key":"3299_CR22","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1097\/01.HS9.0000564104.83392.dc","volume":"3","author":"C McNamara","year":"2019","unstructured":"McNamara C, Spiegel J, Xu W, Kennedy J, Arruda A, Yu M, et al. PS1460 long-term follow up of JAK inhibitor (JAKI) treated patients with myelofibrosis: impact of molecular enhanced integrated scoring systems and type of jaki therapy failure on survival. HemaSphere. 2019;3(S1):672\u20133.","journal-title":"HemaSphere"},{"issue":"6","key":"3299_CR23","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/cncr.32664","volume":"126","author":"F Palandri","year":"2020","unstructured":"Palandri F, Breccia M, Bonifacio M, Polverelli N, Elli EM, Benevolo G, et al. Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer. 2020;126(6):1243\u201352. https:\/\/doi.org\/10.1002\/cncr.32664.","journal-title":"Cancer"},{"issue":"7","key":"3299_CR24","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1080\/13696998.2020.1741381","volume":"23","author":"J Mascarenhas","year":"2020","unstructured":"Mascarenhas J, Mehra M, He J, Potluri R, Loefgren C. Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis. J Med Econ. 2020;23(7):721\u20137. https:\/\/doi.org\/10.1080\/13696998.2020.1741381.","journal-title":"J Med Econ"},{"issue":"6","key":"3299_CR25","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/ejh.13330","volume":"103","author":"F Schain","year":"2019","unstructured":"Schain F, Vago E, Song C, He J, Liwing J, Lofgren C, et al. Survival outcomes in myelofibrosis patients treated with ruxolitinib: a population-based cohort study in Sweden and Norway. Eur J Haematol. 2019;103(6):614\u20139. https:\/\/doi.org\/10.1111\/ejh.13330.","journal-title":"Eur J Haematol"},{"key":"3299_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(21)01822-X","author":"C Harrison","year":"2021","unstructured":"Harrison C, Kiladjian J, Verstovsek S, Vannucchi A, Mesa R, Reiter A, et al. Overall and progression-free survival in patients treated with fedratinib as first-line myelofibrosis (MF) therapy and after prior ruxolitinib (rux): results from the jakarta and Jakarta2 Trials. EHA Annu. 2021. https:\/\/doi.org\/10.1016\/S2152-2650(21)01822-X.","journal-title":"EHA Annu"},{"issue":"Supplement 1","key":"3299_CR27","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1182\/blood-2020-135872","volume":"136","author":"S Verstovsek","year":"2020","unstructured":"Verstovsek S, Egyed M, Lech-Mara\u0144da E, Sacha T, Dubruille V, Oh ST, et al. Robust overall survival and sustained efficacy outcomes during long term exposure to momelotinib in JAK inhibitor na\u00efve and previously jak inhibitor treated intermediate\/high risk myelofibrosis patients. Blood. 2020;136(Supplement 1):51\u20132. https:\/\/doi.org\/10.1182\/blood-2020-135872.","journal-title":"Blood"},{"issue":"6735","key":"3299_CR28","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/20974","volume":"399","author":"C Dhalluin","year":"1999","unstructured":"Dhalluin C, Carlson JE, Zeng L, He C, Aggarwal AK, Zhou MM. Structure and ligand of a histone acetyltransferase bromodomain. Nature. 1999;399(6735):491\u20136. https:\/\/doi.org\/10.1038\/20974.","journal-title":"Nature"},{"issue":"15","key":"3299_CR29","doi-asserted-by":"publisher","first-page":"8758","DOI":"10.1073\/pnas.1433065100","volume":"100","author":"A Dey","year":"2003","unstructured":"Dey A, Chitsaz F, Abbasi A, Misteli T, Ozato K. The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proc Natl Acad Sci USA. 2003;100(15):8758\u201363. https:\/\/doi.org\/10.1073\/pnas.1433065100.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"3299_CR30","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.cell.2012.02.013","volume":"149","author":"P Filippakopoulos","year":"2012","unstructured":"Filippakopoulos P, Picaud S, Mangos M, Keates T, Lambert JP, Barsyte-Lovejoy D, et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell. 2012;149(1):214\u201331. https:\/\/doi.org\/10.1016\/j.cell.2012.02.013.","journal-title":"Cell"},{"issue":"5","key":"3299_CR31","first-page":"659","volume":"12","author":"R Sanchez","year":"2009","unstructured":"Sanchez R, Zhou MM. The role of human bromodomains in chromatin biology and gene transcription. Curr Opin Drug Discov Devel. 2009;12(5):659\u201365.","journal-title":"Curr Opin Drug Discov Devel"},{"issue":"7327","key":"3299_CR32","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/nature09589","volume":"468","author":"E Nicodeme","year":"2010","unstructured":"Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung CW, et al. Suppression of inflammation by a synthetic histone mimic. Nature. 2010;468(7327):1119\u201323. https:\/\/doi.org\/10.1038\/nature09589.","journal-title":"Nature"},{"issue":"4","key":"3299_CR33","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ccell.2018.03.024","volume":"33","author":"M Kleppe","year":"2018","unstructured":"Kleppe M, Koche R, Zou L, van Galen P, Hill CE, Dong L, et al. Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms. Cancer Cell. 2018;33(4):785\u20137. https:\/\/doi.org\/10.1016\/j.ccell.2018.03.024.","journal-title":"Cancer Cell"},{"key":"3299_CR34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-150172","author":"M Kremyanskaya","year":"2021","unstructured":"Kremyanskaya M, Mascarenhas J, Palandri F, Vannucchi A, Verstovsek S, Harrison C, et al. Pelabresib (CPI-0610) monotherapy in patients with myelofibrosis\u2014update of clinical and translational data from the ongoing manifest trial. Blood. 2021. https:\/\/doi.org\/10.1182\/blood-2021-150172.","journal-title":"Blood"},{"key":"3299_CR35","unstructured":"Verstovsek S, Mascarenhas J, Kremyanskaya M, Hoffman R, Rampal R, Gupta V et al. CPI-0610, Bromodomain and Extraterminal Domain Protein (BET) Inhibitor, As \u201cAdd-on\u201d to Ruxolitinib, in Advanced Myelofibrosis Patients with Suboptimal Response: Update of MANIFEST Phase 2 Study. ASH Annual Meeting2020. p. Abstract 56."},{"key":"3299_CR36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128211","author":"J Mascarenhas","year":"2020","unstructured":"Mascarenhas J, Harrison C, Patriarca A, Devos T, Palandri F, Rampal R, et al. CPI-0610, a bromodomain and extraterminal domain protein (BET) inhibitor, in combination with ruxolitinib, in JAK-inhibitor-na\u00efve myelofibrosis patients. Blood. 2020. https:\/\/doi.org\/10.1182\/blood-2019-128211.","journal-title":"Blood"},{"issue":"9","key":"3299_CR37","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1038\/leu.2012.157","volume":"26","author":"A Sprussel","year":"2012","unstructured":"Sprussel A, Schulte JH, Weber S, Necke M, Handschke K, Thor T, et al. Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation. Leukemia. 2012;26(9):2039\u201351. https:\/\/doi.org\/10.1038\/leu.2012.157.","journal-title":"Leukemia"},{"issue":"1","key":"3299_CR38","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1182\/blood-2014-04-569525","volume":"124","author":"D Niebel","year":"2014","unstructured":"Niebel D, Kirfel J, Janzen V, Holler T, Majores M, Gutgemann I. Lysine-specific demethylase 1 (LSD1) in hematopoietic and lymphoid neoplasms. Blood. 2014;124(1):151\u20132. https:\/\/doi.org\/10.1182\/blood-2014-04-569525.","journal-title":"Blood"},{"issue":"3","key":"3299_CR39","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000054","volume":"2","author":"JS Jutzi","year":"2018","unstructured":"Jutzi JS, Kleppe M, Dias J, Staehle HF, Shank K, Teruya-Feldstein J, et al. lsd1 inhibition prolongs survival in mouse models of MPN by selectively targeting the disease clone. Hemasphere. 2018;2(3): e54. https:\/\/doi.org\/10.1097\/HS9.0000000000000054.","journal-title":"Hemasphere"},{"issue":"Supplement 1","key":"3299_CR40","doi-asserted-by":"publisher","first-page":"139-","DOI":"10.1182\/blood-2021-148682","volume":"138","author":"H Gill","year":"2021","unstructured":"Gill H, Yacoub A, Pettit KM, Bradley T, Gerds AT, Tatarczuch M, et al. A phase 2 study of the lsd1 inhibitor img-7289 (bomedemstat) for the treatment of advanced myelofibrosis. Blood. 2021;138(Supplement 1):139-.","journal-title":"Blood"},{"issue":"7","key":"3299_CR41","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2012971.","journal-title":"N Engl J Med"},{"issue":"3","key":"3299_CR42","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0168-9525(00)89010-1","volume":"11","author":"SJ Korsmeyer","year":"1995","unstructured":"Korsmeyer SJ. Regulators of cell death. Trends Genet. 1995;11(3):101\u20135. https:\/\/doi.org\/10.1016\/S0168-9525(00)89010-1.","journal-title":"Trends Genet"},{"issue":"4","key":"3299_CR43","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.celrep.2013.10.038","volume":"5","author":"M Waibel","year":"2013","unstructured":"Waibel M, Solomon VS, Knight DA, Ralli RA, Kim SK, Banks KM, et al. Combined targeting of JAK2 and Bcl-2\/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors. Cell Rep. 2013;5(4):1047\u201359. https:\/\/doi.org\/10.1016\/j.celrep.2013.10.038.","journal-title":"Cell Rep"},{"issue":"20","key":"3299_CR44","doi-asserted-by":"publisher","first-page":"4284","DOI":"10.1182\/blood-2010-04-279125","volume":"116","author":"M Lu","year":"2010","unstructured":"Lu M, Wang J, Li Y, Berenzon D, Wang X, Mascarenhas J, et al. Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon alpha specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells. Blood. 2010;116(20):4284\u20137. https:\/\/doi.org\/10.1182\/blood-2010-04-279125.","journal-title":"Blood"},{"issue":"18","key":"3299_CR45","doi-asserted-by":"publisher","first-page":"10978","DOI":"10.1111\/jcmm.15730","volume":"24","author":"J Petiti","year":"2020","unstructured":"Petiti J, Lo Iacono M, Rosso V, Andreani G, Jovanovski A, Podesta M, et al. Bcl-xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms. J Cell Mol Med. 2020;24(18):10978\u201386. https:\/\/doi.org\/10.1111\/jcmm.15730.","journal-title":"J Cell Mol Med"},{"key":"3299_CR46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136938","author":"N Pemmaraju","year":"2020","unstructured":"Pemmaraju N, Garcia J, Potluri J, Holes L, Harb J, Jung P, et al. The addition of navitoclax to ruxolitinib demonstrates efficacy within different high-risk populations in patients with relapsed\/refractory myelofibrosis. Blood. 2020. https:\/\/doi.org\/10.1182\/blood-2020-136938.","journal-title":"Blood"},{"issue":"6","key":"3299_CR47","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","volume":"170","author":"ER Kastenhuber","year":"2017","unstructured":"Kastenhuber ER, Lowe SW. Putting p53 in Context. Cell. 2017;170(6):1062\u201378. https:\/\/doi.org\/10.1016\/j.cell.2017.08.028.","journal-title":"Cell"},{"issue":"15","key":"3299_CR48","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","volume":"379","author":"J Grinfeld","year":"2018","unstructured":"Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, et al. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018;379(15):1416\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1716614.","journal-title":"N Engl J Med"},{"issue":"24","key":"3299_CR49","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1182\/bloodadvances.2018024018","volume":"2","author":"BK Marcellino","year":"2018","unstructured":"Marcellino BK, Hoffman R, Tripodi J, Lu M, Kosiorek H, Mascarenhas J, et al. Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53. Blood Adv. 2018;2(24):3581\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2018024018.","journal-title":"Blood Adv"},{"issue":"17","key":"3299_CR50","doi-asserted-by":"publisher","first-page":"5318","DOI":"10.1158\/1078-0432.CCR-07-5136","volume":"14","author":"S Shangary","year":"2008","unstructured":"Shangary S, Wang S. Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res. 2008;14(17):5318\u201324. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-5136.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"3299_CR51","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1182\/blood-2012-02-410712","volume":"120","author":"M Lu","year":"2012","unstructured":"Lu M, Wang X, Li Y, Tripodi J, Mosoyan G, Mascarenhas J, et al. Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-alpha 2a specifically targets JAK2V617F-positive polycythemia vera cells. Blood. 2012;120(15):3098\u2013105. https:\/\/doi.org\/10.1182\/blood-2012-02-410712.","journal-title":"Blood"},{"issue":"6","key":"3299_CR52","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1182\/blood.2018893545","volume":"134","author":"J Mascarenhas","year":"2019","unstructured":"Mascarenhas J, Lu M, Kosiorek H, Virtgaym E, Xia L, Sandy L, et al. Oral idasanutlin in patients with polycythemia vera. Blood. 2019;134(6):525\u201333. https:\/\/doi.org\/10.1182\/blood.2018893545.","journal-title":"Blood"},{"key":"3299_CR53","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-135868","author":"J Mascarenhas","year":"2020","unstructured":"Mascarenhas J, Higgins B, Anders D, Burbury K, El-Galaly T, Gerds A, et al. Safety and efficacy of idasanutlin in patients (pts) with hydroxyurea (HU)-resistant\/intolerant polycythemia vera (PV): results of an international phase II study. Blood. 2020. https:\/\/doi.org\/10.1182\/blood-2020-135868.","journal-title":"Blood"},{"key":"3299_CR54","unstructured":"Al-Ali H, Delgado R, Lange A, Pluta A, McLornan D, Vachhani P et al (2020) KRT\u2011232, a first\u2011in\u2011class, murine double minute 2 inhibitor (MDM2I), for myelofibrosis (MF) relapsed or refractory (R\/R) to janus\u2011associated kinase inhibitor (JAKI) treatment (TX). EHA Annual Meeting. p. Abstract S215"},{"issue":"Supplement 1","key":"3299_CR55","doi-asserted-by":"publisher","first-page":"3581-","DOI":"10.1182\/blood-2021-147543","volume":"138","author":"P Vachani","year":"2021","unstructured":"Vachani P, Lange A, Delgado RG, Al-Ali HK, Hern\u00e1ndez-Rivas JM, Kiladjian J-J, et al. Potential disease-modifying activity of navtemadlin (KRT-232), a first-in-class MDM2 inhibitor, correlates with clinical benefits in relapsed\/refractory myelofibrosis (MF). Blood. 2021;138(Supplement 1):3581-.","journal-title":"Blood"},{"issue":"Suppl 2","key":"3299_CR56","doi-asserted-by":"publisher","first-page":"S307","DOI":"10.1016\/j.clml.2013.07.011","volume":"13","author":"N Bartalucci","year":"2013","unstructured":"Bartalucci N, Guglielmelli P, Vannucchi AM. Rationale for targeting the PI3K\/Akt\/mTOR pathway in myeloproliferative neoplasms. Clin Lymphoma Myeloma Leuk. 2013;13(Suppl 2):S307\u20139. https:\/\/doi.org\/10.1016\/j.clml.2013.07.011.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"3299_CR57","doi-asserted-by":"publisher","first-page":"954","DOI":"10.18632\/oncotarget.652","volume":"3","author":"JA McCubrey","year":"2012","unstructured":"McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, et al. Mutations and deregulation of Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR cascades which alter therapy response. Oncotarget. 2012;3(9):954\u201387. https:\/\/doi.org\/10.18632\/oncotarget.652.","journal-title":"Oncotarget"},{"issue":"1","key":"3299_CR58","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12943-019-0954-x","volume":"18","author":"J Yang","year":"2019","unstructured":"Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer. 2019;18(1):26. https:\/\/doi.org\/10.1186\/s12943-019-0954-x.","journal-title":"Mol Cancer"},{"issue":"4","key":"3299_CR59","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/j.1365-2141.2009.07870.x","volume":"147","author":"LF Grimwade","year":"2009","unstructured":"Grimwade LF, Happerfield L, Tristram C, McIntosh G, Rees M, Bench AJ, et al. Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms. Br J Haematol. 2009;147(4):495\u2013506. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07870.x.","journal-title":"Br J Haematol"},{"issue":"7037","key":"3299_CR60","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144\u20138. https:\/\/doi.org\/10.1038\/nature03546.","journal-title":"Nature"},{"issue":"1","key":"3299_CR61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054826","volume":"8","author":"C Bogani","year":"2013","unstructured":"Bogani C, Bartalucci N, Martinelli S, Tozzi L, Guglielmelli P, Bosi A, et al. mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms. PLoS ONE. 2013;8(1): e54826. https:\/\/doi.org\/10.1371\/journal.pone.0054826.","journal-title":"PLoS ONE"},{"issue":"8","key":"3299_CR62","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1182\/blood-2011-01-330563","volume":"118","author":"P Guglielmelli","year":"2011","unstructured":"Guglielmelli P, Barosi G, Rambaldi A, Marchioli R, Masciulli A, Tozzi L, et al. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1\/2 study in patients with myelofibrosis. Blood. 2011;118(8):2069\u201376. https:\/\/doi.org\/10.1182\/blood-2011-01-330563.","journal-title":"Blood"},{"issue":"12","key":"3299_CR63","doi-asserted-by":"publisher","first-page":"e551","DOI":"10.3324\/haematol.2018.209965","volume":"104","author":"ST Durrant","year":"2019","unstructured":"Durrant ST, Nagler A, Guglielmelli P, Lavie D, le Coutre P, Gisslinger H, et al. Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis. Haematologica. 2019;104(12):e551\u20134. https:\/\/doi.org\/10.3324\/haematol.2018.209965.","journal-title":"Haematologica"},{"issue":"7","key":"3299_CR64","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1158\/2159-8290.CD-11-0249","volume":"1","author":"DA Fruman","year":"2011","unstructured":"Fruman DA, Rommel C. PI3Kdelta inhibitors in cancer: rationale and serendipity merge in the clinic. Cancer Discov. 2011;1(7):562\u201372. https:\/\/doi.org\/10.1158\/2159-8290.CD-11-0249.","journal-title":"Cancer Discov"},{"key":"3299_CR65","unstructured":"Yacoub A, Wang E, Rampal R, Borate U, Kremyanskaya M, Ali H. et al (2020) addition of parsaclisib, a pi3kdelta inhibitor, in patients (PTS) with suboptimal response to ruxolitinib (RUX): a phase 2 study in pts with myelofibrosis (MF). EHA Annual Meeting. p. Abstract S216"},{"issue":"6","key":"3299_CR66","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3324\/haematol.2015.141283","volume":"101","author":"AA Zahr","year":"2016","unstructured":"Zahr AA, Salama ME, Carreau N, Tremblay D, Verstovsek S, Mesa R, et al. Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies. Haematologica. 2016;101(6):660\u201371. https:\/\/doi.org\/10.3324\/haematol.2015.141283.","journal-title":"Haematologica"},{"issue":"3","key":"3299_CR67","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1182\/blood-2006-12-064626","volume":"110","author":"SO Ciurea","year":"2007","unstructured":"Ciurea SO, Merchant D, Mahmud N, Ishii T, Zhao Y, Hu W, et al. Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood. 2007;110(3):986\u201393. https:\/\/doi.org\/10.1182\/blood-2006-12-064626.","journal-title":"Blood"},{"issue":"6","key":"3299_CR68","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1182\/blood-2008-04-146480","volume":"113","author":"S Yamazaki","year":"2009","unstructured":"Yamazaki S, Iwama A, Takayanagi S, Eto K, Ema H, Nakauchi H. TGF-beta as a candidate bone marrow niche signal to induce hematopoietic stem cell hibernation. Blood. 2009;113(6):1250\u20136. https:\/\/doi.org\/10.1182\/blood-2008-04-146480.","journal-title":"Blood"},{"issue":"3","key":"3299_CR69","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1084\/jem.20121610","volume":"210","author":"F Brenet","year":"2013","unstructured":"Brenet F, Kermani P, Spektor R, Rafii S, Scandura JM. TGFbeta restores hematopoietic homeostasis after myelosuppressive chemotherapy. J Exp Med. 2013;210(3):623\u201339. https:\/\/doi.org\/10.1084\/jem.20121610.","journal-title":"J Exp Med"},{"issue":"1","key":"3299_CR70","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1084\/jem.20030980","volume":"199","author":"JC Langer","year":"2004","unstructured":"Langer JC, Henckaerts E, Orenstein J, Snoeck HW. Quantitative trait analysis reveals transforming growth factor-beta2 as a positive regulator of early hematopoietic progenitor and stem cell function. J Exp Med. 2004;199(1):5\u201314. https:\/\/doi.org\/10.1084\/jem.20030980.","journal-title":"J Exp Med"},{"key":"3299_CR71","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.145651","author":"L Varricchio","year":"2021","unstructured":"Varricchio L, Iancu-Rubin C, Upadhyaya B, Zingariello M, Martelli F, Verachi P, et al. TGFbeta1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis. JCI Insight. 2021. https:\/\/doi.org\/10.1172\/jci.insight.145651.","journal-title":"JCI Insight"},{"issue":"Supplement 1","key":"3299_CR72","doi-asserted-by":"publisher","first-page":"142-","DOI":"10.1182\/blood-2021-148995","volume":"138","author":"J Mascarenhas","year":"2021","unstructured":"Mascarenhas J, Kosiorek HE, Bhave R, Palmer JM, Kuykendall AT, Mesa RA, et al. Treatment of myelofibrosis patients with the TGF-\u03b2 1\/3 inhibitor AVID200 (MPN-RC 118) induces a profound effect on platelet production. Blood. 2021;138(Supplement 1):142-.","journal-title":"Blood"},{"issue":"5","key":"3299_CR73","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1358\/dnp.2010.23.5.1444206","volume":"23","author":"JS Duffield","year":"2010","unstructured":"Duffield JS, Lupher ML Jr. PRM-151 (recombinant human serum amyloid P\/pentraxin 2) for the treatment of fibrosis. Drug News Perspect. 2010;23(5):305\u201315. https:\/\/doi.org\/10.1358\/dnp.2010.23.5.1444206.","journal-title":"Drug News Perspect"},{"issue":"10","key":"3299_CR74","doi-asserted-by":"publisher","first-page":"5537","DOI":"10.4049\/jimmunol.171.10.5537","volume":"171","author":"D Pilling","year":"2003","unstructured":"Pilling D, Buckley CD, Salmon M, Gomer RH. Inhibition of fibrocyte differentiation by serum amyloid P. J Immunol. 2003;171(10):5537\u201346. https:\/\/doi.org\/10.4049\/jimmunol.171.10.5537.","journal-title":"J Immunol"},{"issue":"22","key":"3299_CR75","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1001\/jama.2018.6129","volume":"319","author":"G Raghu","year":"2018","unstructured":"Raghu G, van den Blink B, Hamblin MJ, Brown AW, Golden JA, Ho LA, et al. Effect of recombinant human pentraxin 2 vs placebo on change in forced vital capacity in patients with idiopathic pulmonary fibrosis: a randomized clinical trial. JAMA J Am Med Assoc. 2018;319(22):2299\u2013307. https:\/\/doi.org\/10.1001\/jama.2018.6129.","journal-title":"JAMA J Am Med Assoc"},{"issue":"9","key":"3299_CR76","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1084\/jem.20160283","volume":"213","author":"S Verstovsek","year":"2016","unstructured":"Verstovsek S, Manshouri T, Pilling D, Bueso-Ramos CE, Newberry KJ, Prijic S, et al. Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. J Exp Med. 2016;213(9):1723\u201340. https:\/\/doi.org\/10.1084\/jem.20160283.","journal-title":"J Exp Med"},{"issue":"Supplement 1","key":"3299_CR77","doi-asserted-by":"publisher","first-page":"686-","DOI":"10.1182\/blood-2018-99-115362","volume":"132","author":"S Verstovsek","year":"2018","unstructured":"Verstovsek S, Hasserjian RP, Pozdnyakova O, Veletic I, Mesa RA, Foltz L, et al. PRM-151 in myelofibrosis: efficacy and safety in an open label extension study. Blood. 2018;132(Supplement 1):686-. https:\/\/doi.org\/10.1182\/blood-2018-99-115362.","journal-title":"Blood"},{"key":"3299_CR78","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000561592.51072.9b","author":"S Verstovsek","year":"2019","unstructured":"Verstovsek S, Talpaz M, Wadleigh M, Palmer J, Isidori A, te Boekhorst P, et al. A randomized, double blind phase 2 study of 3 different doses of prm-151 in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib. HemaSphere. 2019. https:\/\/doi.org\/10.1097\/01.HS9.0000561592.51072.9b.","journal-title":"HemaSphere."},{"issue":"3","key":"3299_CR79","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/0092-8674(89)90035-4","volume":"59","author":"GB Morin","year":"1989","unstructured":"Morin GB. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell. 1989;59(3):521\u20139.","journal-title":"Cell"},{"issue":"5193","key":"3299_CR80","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1126\/science.7605428","volume":"266","author":"NW Kim","year":"1994","unstructured":"Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266(5193):2011\u20135.","journal-title":"Science"},{"issue":"7","key":"3299_CR81","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.exphem.2013.03.007","volume":"41","author":"M Ruella","year":"2013","unstructured":"Ruella M, Salmoiraghi S, Risso A, Carobbio A, Buttiglieri S, Spatola T, et al. Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy. Exp Hematol. 2013;41(7):627\u201334. https:\/\/doi.org\/10.1016\/j.exphem.2013.03.007.","journal-title":"Exp Hematol"},{"issue":"18","key":"3299_CR82","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1182\/bloodadvances.2018022012","volume":"2","author":"X Wang","year":"2018","unstructured":"Wang X, Hu CS, Petersen B, Qiu J, Ye F, Houldsworth J, et al. Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells. Blood Adv. 2018;2(18):2378\u201388. https:\/\/doi.org\/10.1182\/bloodadvances.2018022012.","journal-title":"Blood Adv"},{"issue":"10","key":"3299_CR83","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1056\/NEJMoa1310523","volume":"373","author":"A Tefferi","year":"2015","unstructured":"Tefferi A, Lasho TL, Begna KH, Patnaik MM, Zblewski DL, Finke CM, et al. A pilot study of the telomerase inhibitor imetelstat for myelofibrosis. N Engl J Med. 2015;373(10):908\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1310523.","journal-title":"N Engl J Med"},{"issue":"26","key":"3299_CR84","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1200\/JCO.20.02864","volume":"39","author":"J Mascarenhas","year":"2021","unstructured":"Mascarenhas J, Komrokji RS, Palandri F, Martino B, Niederwieser D, Reiter A, et al. Randomized, single-blind, multicenter phase II study of two doses of imetelstat in relapsed or refractory myelofibrosis. J Clin Oncol. 2021;39(26):2881\u201392. https:\/\/doi.org\/10.1200\/JCO.20.02864.","journal-title":"J Clin Oncol"},{"key":"3299_CR85","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04683-w","author":"AT Kuykendall","year":"2021","unstructured":"Kuykendall AT, Sun L, Mascarenhas J, Kiladjian JJ, Vannucchi AM, Wang J, et al. Favorable overall survival with imetelstat in relapsed\/refractory myelofibrosis patients compared with real-world data. Ann Hematol. 2021. https:\/\/doi.org\/10.1007\/s00277-021-04683-w.","journal-title":"Ann Hematol"},{"issue":"5","key":"3299_CR86","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1158\/2159-8290.CD-13-1005","volume":"4","author":"DS Tan","year":"2014","unstructured":"Tan DS, Bedard PL, Kuruvilla J, Siu LL, Razak AR. Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy. Cancer Discov. 2014;4(5):527\u201337. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-1005.","journal-title":"Cancer Discov"},{"issue":"8","key":"3299_CR87","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381(8):727\u201338. https:\/\/doi.org\/10.1056\/NEJMoa1903455.","journal-title":"N Engl J Med"},{"issue":"7","key":"3299_CR88","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1158\/1078-0432.CCR-18-0959","volume":"25","author":"D Yan","year":"2019","unstructured":"Yan D, Pomicter AD, Tantravahi S, Mason CC, Senina AV, Ahmann JM, et al. Nuclear-cytoplasmic transport is a therapeutic target in myelofibrosis. Clin Cancer Res. 2019;25(7):2323\u201335. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0959.","journal-title":"Clin Cancer Res"},{"issue":"Supplement 1","key":"3299_CR89","doi-asserted-by":"publisher","first-page":"143-","DOI":"10.1182\/blood-2021-153940","volume":"138","author":"SK Tantravahi","year":"2021","unstructured":"Tantravahi SK, Kim SJ, Sundar D, Patel AB, Pomicter AD, Boucher KM, et al. A phase 2 study to evaluate the efficacy and safety of selinexor in patients with myelofibrosis refractory or intolerant to JAK inhibitors. Blood. 2021;138(Supplement 1):143-.","journal-title":"Blood"},{"issue":"10","key":"3299_CR90","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","volume":"14","author":"CT Jordan","year":"2000","unstructured":"Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14(10):1777\u201384. https:\/\/doi.org\/10.1038\/sj.leu.2401903.","journal-title":"Leukemia"},{"issue":"1","key":"3299_CR91","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2050-7771-2-4","volume":"2","author":"U Testa","year":"2014","unstructured":"Testa U, Pelosi E, Frankel A. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomark Res. 2014;2(1):4. https:\/\/doi.org\/10.1186\/2050-7771-2-4.","journal-title":"Biomark Res"},{"issue":"3","key":"3299_CR92","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.hemonc.2019.01.001","volume":"12","author":"Y Bao","year":"2019","unstructured":"Bao Y, Hu W, Guo Y, Yang W. Phenotypic characterization of malignant progenitor cells in patients with idiopathic myelofibrosis. Hematol Oncol Stem Cell Ther. 2019;12(3):146\u201354. https:\/\/doi.org\/10.1016\/j.hemonc.2019.01.001.","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"21","key":"3299_CR93","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.1182\/blood.V124.21.5577.5577","volume":"124","author":"T Lasho","year":"2014","unstructured":"Lasho T, Finke C, Kimlinger TK, Zblewski D, Chen D, Patnaik MM, et al. Expression of CD123 (IL-3R-alpha), a therapeutic target of SL-401, on myeloproliferative neoplasms. Blood. 2014;124(21):5577. https:\/\/doi.org\/10.1182\/blood.V124.21.5577.5577.","journal-title":"Blood"},{"issue":"17","key":"3299_CR94","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","volume":"380","author":"N Pemmaraju","year":"2019","unstructured":"Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019;380(17):1628\u201337. https:\/\/doi.org\/10.1056\/NEJMoa1815105.","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"3299_CR95","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1182\/blood-2021-145276","volume":"138","author":"A Yacoub","year":"2021","unstructured":"Yacoub A, Patnaik MM, Ali H, Wang ES, Gupta V, Lee S, et al. A phase 1\/2 study of single agent tagraxofusp, a first-in-class CD123-targeted therapy, in patients with myelofibrosis that is relapsed\/refractory following JAK inhibitor therapy. Blood. 2021;138(Supplement 1):140.","journal-title":"Blood"},{"issue":"9","key":"3299_CR96","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/leu.2011.95","volume":"25","author":"U Blank","year":"2011","unstructured":"Blank U, Karlsson S. The role of Smad signaling in hematopoiesis and translational hematology. Leukemia. 2011;25(9):1379\u201388. https:\/\/doi.org\/10.1038\/leu.2011.95.","journal-title":"Leukemia"},{"issue":"8","key":"3299_CR97","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1182\/blood-2018-11-876888","volume":"133","author":"P Fenaux","year":"2019","unstructured":"Fenaux P, Kiladjian JJ, Platzbecker U. Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis. Blood. 2019;133(8):790\u20134. https:\/\/doi.org\/10.1182\/blood-2018-11-876888.","journal-title":"Blood"},{"issue":"4","key":"3299_CR98","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/nm.3512","volume":"20","author":"RN Suragani","year":"2014","unstructured":"Suragani RN, Cadena SM, Cawley SM, Sako D, Mitchell D, Li R, et al. Transforming growth factor-beta superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014;20(4):408\u201314. https:\/\/doi.org\/10.1038\/nm.3512.","journal-title":"Nat Med"},{"issue":"Supplement_1","key":"3299_CR99","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1182\/blood-2019-122546","volume":"134","author":"AT Gerds","year":"2019","unstructured":"Gerds AT, Vannucchi AM, Passamonti F, Kremyanskaya M, Gotlib JR, Palmer JM, et al. A phase 2 study of luspatercept in patients with myelofibrosis-associated anemia. Blood. 2019;134(Supplement_1):557. https:\/\/doi.org\/10.1182\/blood-2019-122546.","journal-title":"Blood"},{"issue":"3","key":"3299_CR100","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/cncr.30325","volume":"123","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, et al. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists\/oncologists in the United States: Findings from the MPN Landmark survey. Cancer. 2017;123(3):449\u201358. https:\/\/doi.org\/10.1002\/cncr.30325.","journal-title":"Cancer"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03299-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-022-03299-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03299-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T15:50:52Z","timestamp":1651074652000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-022-03299-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,19]]},"references-count":100,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["3299"],"URL":"https:\/\/doi.org\/10.1007\/s12185-022-03299-8","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,19]]},"assertion":[{"value":"11 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Douglas Tremblay receives contracted research funding paid to his institution from Astellas Pharma and consulting fees from AbbVie and CTI Biopharma. Ruben Mesa receives contracted research funding paid to his institution from Celgene, Incyte, Abbvie, Samus, Genotech, Promedior, CTI Biopharma, Constellation and the Mays Cancer Center P30 Cancer Center Support Grant from the National Cancer Institute (CA054174). He receives consulting fees from Novartis, Sierra Oncology, LaJolla Pharmaceutical, and Constellation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}